Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
FORM 4
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Cencora distributes pharmaceuticals and healthcare products to pharmacies, hospitals, and healthcare providers globally, operating one of the largest pharmaceutical distribution networks alongside a smaller number of major competitors.
Business model
The company earns revenue primarily from distributing pharmaceutical products at high volume and low margin, with profitability driven by scale efficiencies and effective working capital management similar to other major pharmaceutical distributors.
Growth drivers
- Prescription drug volume growth tied to an aging population
- Specialty pharmaceutical distribution growth
- International distribution expansion
- Continued efficiency improvements in its distribution network
Competitive position
Cencora's massive scale and distribution infrastructure give it significant cost advantages in an industry with thin margins, where scale is essential to profitability, supporting its position as one of a small number of major distributors globally.
Risks
Distribution margins are inherently thin and sensitive to drug pricing dynamics, customer concentration among large pharmacy chains creates contract renewal risk, and litigation related to opioid distribution has been an ongoing industry wide concern.
Valuation
Cencora trades at a moderate multiple typical of pharmaceutical distributors, with the market valuing its consistent, if low margin, cash flow generation and scale advantages.
Final view
Cencora's scale in pharmaceutical distribution provides steady, if low margin, cash flow generation similar to other major distributors. My view is neutral to favorable, with continued volume growth and specialty distribution expansion supporting the long term outlook.
Overall rating: 70/100
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.